头孢泊肟对从癌症患者分离出的细菌菌株的体外活性。

In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer.

作者信息

Rolston K V, Messer M, Nguyen H, Ho D, LeBlanc B, Bodey G P

机构信息

Department of Medical Specialties, University of Texas M.D. Anderson Cancer Center, Houston.

出版信息

Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):581-5. doi: 10.1007/BF01967278.

DOI:10.1007/BF01967278

PMID:1915401

Abstract

The in vitro activity of cefpodoxime, an oral cephalosporin ester, against 792 bacterial isolates representing 36 species was evaluated in comparison to that of ciprofloxacin and trimethoprim/sulfamethoxazole (TMP/SMX). Cefpodoxime inhibited the majority of Streptococcus spp., Haemophilus influenzae and Proteus mirabilis at a concentration of less than or equal to 0.12 microgram/ml. It was also active against Citrobacter diversus, Escherichia coli, Klebsiella spp., Proteus vulgaris, Serratia marcescens and methicillin-susceptible Staphylococcus aureus isolates. Overall, cefpodoxime appeared to be less active than ciprofloxacin and TMP/SMX against many pathogens common in cancer patients.

摘要

与环丙沙星和甲氧苄啶/磺胺甲恶唑（TMP/SMX）相比，评估了口服头孢菌素酯头孢泊肟对代表36个菌种的792株细菌分离株的体外活性。头孢泊肟在浓度小于或等于0.12微克/毫升时可抑制大多数链球菌属、流感嗜血杆菌和奇异变形杆菌。它对分散柠檬酸杆菌、大肠杆菌、克雷伯菌属、普通变形杆菌、粘质沙雷菌和甲氧西林敏感金黄色葡萄球菌分离株也有活性。总体而言，头孢泊肟对癌症患者常见的许多病原体的活性似乎低于环丙沙星和TMP/SMX。